What is Schrodinger?
Founded in 1990, Schrodinger provides advanced molecular simulations and enterprise software solutions that are essential for modern drug discovery and materials research. The company's core value proposition lies in its ability to accelerate innovation through computational methods, effectively reducing the time and cost associated with traditional laboratory experimentation. By integrating physics-based modeling with machine learning, Schrodinger empowers researchers in biotechnology, pharmaceuticals, chemicals, and electronics to predict molecular properties with unprecedented accuracy.
The company operates as a vital infrastructure provider for the life sciences industry, maintaining a robust portfolio of strategic partnerships. Its global presence allows it to serve a diverse client base, facilitating breakthroughs that range from novel therapeutic development to the creation of high-performance materials. As a leader in the computational chemistry space, Schrodinger continues to define the standard for digital transformation in scientific research.
How much funding has Schrodinger raised?
Schrodinger has raised a total of $137M across 5 funding rounds:
Other Financing Round
$10M
Other Financing Round
$20M
Other Financing Round
$22M
Unspecified
$85M
Series A
$14M
Other Financing Round (2010): $10M with participation from Cascade Investment
Other Financing Round (2012): $20M led by Bill Gates
Other Financing Round (2015): $22M supported by Scott Becker
Unspecified (2019): $85M featuring Deerfield Management, GV, Qiming Venture Partners, Bill & Melinda Gates Foundation, WuXi AppTec's Corporate Venture Fund, and Baron
Series A (2020): $14M backed by Canaan, Grey Wolf Therapeutics, and Andera Partners
Key Investors in Schrodinger
Canaan
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
Bill Gates
Gates Notes serves as a platform for sharing insights on global development, literature, and learning, reflecting the personal investment interests of Bill Gates.
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the healthcare ecosystem with flexible funding models.
What's next for Schrodinger?
Looking ahead, Schrodinger is well-positioned to leverage its recent strategic investment to further integrate artificial intelligence into its simulation workflows. The company's focus remains on scaling its enterprise software platform to address increasingly complex challenges in drug discovery and materials design. By deepening its collaborative ecosystem with global partners, Schrodinger aims to solidify its market dominance and drive the next generation of scientific breakthroughs.
The ongoing commitment from high-profile investors suggests a strong confidence in the company's long-term growth trajectory. As the demand for computational efficiency in R&D continues to rise, Schrodinger is expected to expand its reach into emerging markets and explore new frontiers in frontier technology, ensuring its technology remains the primary engine for innovation in the global scientific community.
